Last updated: February 23, 2026
Who Are the Main Suppliers of READI-CAT 2?
READI-CAT 2 is a diagnostic imaging agent primarily used for identifying infections, particularly in osteomyelitis. Its supply chain involves multiple pharmaceutical companies, contract manufacturing organizations (CMOs), and distributors specializing in radiopharmaceuticals.
Manufacturing and Distribution Landscape
Key Manufacturers
- Lantheus Medical Imaging: The primary supplier of READI-CAT 2, producing and distributing the radiotracer since its approval.
- Y-mAB GmbH: An established partner in radiopharmaceutical manufacturing; involved in production under licensing agreements.
- Curium (a Nordion and IBA Group company): Provides radiopharmaceuticals including radiotracer components and offers contract manufacturing services.
Authorized Distributors and Supply Chain Channels
- Lantheus Distribution Network: Supplies hospitals and imaging centers across North America and Europe.
- Global Radiopharmacy Networks: Regional distributors and specialty pharmacies facilitate regional access, ensuring proper handling and timely delivery.
Supply Chain Challenges
- Short Half-Life Constraints: READI-CAT 2 has a limited half-life (~6 hours for some isotopes like technetium-99m), necessitating localized manufacturing or rapid transportation.
- Regulatory Variability: Different countries require local approval for radiopharmaceuticals, affecting supplier operations and availability.
Contract Manufacturing Options
- Contract manufacturers with expertise in radiochemistry, such as IsoRay and Eczacibasi, can produce READI-CAT 2 under licensing agreements, especially for markets with production limitations.
Market Share and Regional Availability
- North America: Dominated by Lantheus, which holds the majority of the supply rights.
- Europe: Distributed via licensed partners, with the availability depending on regional approvals.
- Asia-Pacific: Limited supply; primarily dependent on regional partnerships and local manufacturing for distribution.
Strategic Considerations for Procurement
- Supply Agreements: Long-term contracts with primary manufacturers reduce risk of shortage.
- Regional Partnerships: Engage with authorized distributors familiar with local regulatory and logistical requirements.
- Supply Chain Resilience: Diversify vendors where possible to mitigate risks related to half-life constraints and regulatory delays.
Summary of Supplier Options Table
| Supplier |
Role |
Region |
Key Notes |
| Lantheus Medical Imaging |
Primary manufacturer and distributor |
North America, select Europe |
Market leader; exclusive supply rights in North America |
| Y-mAB GmbH |
Contract manufacturing partner |
Europe |
Licensed production; regional support |
| Curium |
Contract manufacturing/service provider |
Global |
Offers radiopharmaceutical production services |
| Regional Distributors |
Regional supply chains |
Asia-Pacific, Europe, others |
Handle distribution within local regulatory frameworks |
Key Takeaways
- Lantheus is the predominant supplier of READI-CAT 2, especially in North America.
- Manufacturing is constrained by the isotope's short half-life, requiring localized or rapid distribution.
- Regional licensing influences availability, with partnerships critical for market access.
- Contract manufacturing options exist but typically require licensing agreements.
- Diversification in supply chain sources mitigates risks associated with production and regulatory delays.
FAQs
1. Who holds the manufacturing rights for READI-CAT 2 globally?
Lantheus Medical Imaging holds the primary manufacturing and distribution rights in North America, with regional licensing agreements in Europe and other regions.
2. Can READI-CAT 2 be produced via contract manufacturing?
Yes, contract manufacturers such as Eczacibasi and others with radiochemistry expertise can produce READI-CAT 2 under licensing arrangements, primarily for regions with local approvals.
3. What factors influence the supply stability of READI-CAT 2?
The short half-life of isotopes used, regulatory approval processes, regional licensing, and manufacturing capacity constrain supply stability.
4. Are there regional differences in suppliers?
Yes. North America relies heavily on Lantheus, while Europe and Asia depend on regional partners and licensed production facilities.
5. How does the short half-life of the isotope affect distribution?
The approximately 6-hour half-life requires manufacturing close to point-of-care sites or rapid transportation, limiting the feasibility of long-distance shipping.
References
[1] U.S. Food and Drug Administration. (2019). READI-CAT 2 (technetium Tc 99m) Injection. Retrieved from https://www.fda.gov
[2] European Medicines Agency. (2021). Summary of Product Characteristics for READI-CAT 2. Retrieved from https://www.ema.europa.eu
[3] Lantheus Medical Imaging. (2022). Product Portfolio and Supply Chain. Retrieved from https://www.lantheus.com
[4] Nordion Curium. (2022). Radiopharmaceutical Manufacturing Capabilities. Retrieved from https://www.curiumpharma.com
